Illumina, San Diego, CA.
Tempus, Chicago, IL.
JCO Precis Oncol. 2024 Jan;8:e2300382. doi: 10.1200/PO.23.00382.
Liquid biopsies-tests that detect circulating tumor cellular components in the bloodstream-have the potential to transform cancer by reducing health inequities in screening, diagnostics, and monitoring. Today, liquid biopsies are being used to guide treatment choices for patients and monitor for cancer recurrence, and promising work in multi-cancer early detection is ongoing. However, without awareness of the barriers to adoption of this new technology and a willingness to build mitigation efforts into the implementation of widespread liquid biopsy testing, the communities that could most benefit may be the last to access and use them. In this work, we review the challenges likely to affect the accessibility of liquid biopsies in both the general population and underserved populations, and recommend specific actions to facilitate equitable access for all patients.
液体活检——检测血液中循环肿瘤细胞成分的检测方法——有可能通过减少筛查、诊断和监测方面的健康不平等现象来改变癌症治疗现状。目前,液体活检正在被用于指导患者的治疗选择,并监测癌症复发情况,同时,多癌种早期检测领域也有令人振奋的工作进展。然而,如果没有意识到采用这项新技术的障碍,并且不愿意在广泛开展液体活检检测时制定缓解措施,那么最需要这项技术的人群可能是最后才能够获得和使用它的人群。在这项工作中,我们回顾了可能影响液体活检在一般人群和服务不足人群中可及性的挑战,并为所有患者提供公平获取机会提出了具体建议。